These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 36342728

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Graves' dermopathy on the big toe].
    Couderc E, Cante V, Renaud O, Guillet G.
    Ann Dermatol Venereol; 2013 May; 140(5):382-5. PubMed ID: 23663712
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Annularly arranged nodular pretibial myxedema after 7-year treatment of Graves' disease.
    Kishimoto I, Chuyen NTH, Okamoto H.
    J Dermatol; 2018 Jan; 45(1):110-111. PubMed ID: 28150342
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ.
    Front Endocrinol (Lausanne); 2020 Jan; 11():610337. PubMed ID: 33391187
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Detection, cellular localization, and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroidal manifestations of Graves' disease.
    Heufelder AE, Wenzel BE, Gorman CA, Bahn RS.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):739-45. PubMed ID: 1890149
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease.
    Anderson CK, Miller OF.
    J Am Acad Dermatol; 2003 Jun; 48(6):970-2. PubMed ID: 12789197
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor.
    Chang TC, Wu SL, Hsiao YL, Kuo ST, Chien LF, Kuo YF, Change CC, Chang TJ.
    Clin Immunol Immunopathol; 1994 Apr; 71(1):113-20. PubMed ID: 8137554
    [Abstract] [Full Text] [Related]

  • 37. Local immune microenvironment of skin may play an important role in the development of pretibial myxedema.
    Chen X, Dong J, Zhang L, Zhao X, Shi R, Pan M, Zheng J.
    Exp Dermatol; 2021 Dec; 30(12):1820-1824. PubMed ID: 34047397
    [Abstract] [Full Text] [Related]

  • 38. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Patrizio A, Camastra S, Miccoli M, Cavallini G, Benvenga S, Antonelli A.
    Front Endocrinol (Lausanne); 2021 Dec; 12():654473. PubMed ID: 33935970
    [Abstract] [Full Text] [Related]

  • 39. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
    Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS.
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.